Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | MLYCD | O95822 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13781506 | 0.88 | MEN1 (0.39) | SIGMAR1DNM1MEN1KMT2A | |
| SCHEMBL21579891 | 0.84 | SIGMAR1 (0.44) | SIGMAR1MLYCDMEN1KMT2A | |
| SCHEMBL18272811 | 0.79 | SIGMAR1 (0.42) | SIGMAR1MLYCD | |
| SCHEMBL8070123 | 0.78 | CACNA1H (0.36) | MAPT | |
| SCHEMBL1827225 | 0.78 | MEN1 (0.54) | DNM1MEN1KMT2A | |
| SCHEMBL8741153 | 0.78 | MEN1 (0.48) | DNM1MEN1KMT2A | |
| SCHEMBL13921016 | 0.77 | SIGMAR1 (0.39) | SIGMAR1MLYCDMEN1KMT2A | |
| SCHEMBL20287596 | 0.76 | SIGMAR1 (0.41) | SIGMAR1MLYCD | |
| SCHEMBL2127728 | 0.76 | MCL1 (0.48) | DNM1MEN1KMT2AMAPT | |
| SCHEMBL9064 | 0.76 | MEN1 (0.58) | SIGMAR1MLYCDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | SIGMAR1 2272/4885MLYCD 1279/4885DNM1 3750/4885 |
| US-20230365511-A1 | Antiviral Pyrazolopiridinone Compounds | ZC3HAV1, ZC3HAV1L, RPL35 | SIGMAR1 3545/4885MLYCD 4094/4885DNM1 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.